<table width="95%" xmlns="urn:hl7-org:v3" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<caption>Table 4: Drugs Having Clinically Important Interactions with Amphetamines</caption>
<col align="left" valign="top" width="25%"></col>
<col align="left" valign="top" width="75%"></col>
<tbody>
<tr stylecode="Botrule">
<td colspan="2" stylecode="Rrule Lrule">
<content stylecode="bold underline">Monoamine Oxidase Inhibitors (MAOIs)</content>
</td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Rrule Lrule">Clinical Impact</td>
<td stylecode="Rrule">Concomitant use of MAOIs and CNS stimulants can cause hypertensive crisis. Potential outcomes include death, stroke, myocardial infarction, aortic dissection, ophthalmological complications, eclampsia, pulmonary edema, and renal failure.</td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Rrule Lrule">Intervention</td>
<td stylecode="Rrule">Do not administer ADDERALL XR concomitantly or within 14 days after discontinuing MAOI <content stylecode="italics">[see <linkhtml href="#LINK_db2cc6df-821d-4598-adef-bb516fa9ddcb">CONTRAINDICATIONS (4)</linkhtml> and <linkhtml href="#S5.6">WARNINGS AND PRECAUTIONS (5.6)</linkhtml>]</content>.</td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Rrule Lrule">Examples</td>
<td stylecode="Rrule">selegiline, tranylcypromine, isocarboxazid, phenelzine, linezolid, methylene blue</td>
</tr>
<tr stylecode="Botrule">
<td colspan="2" stylecode="Rrule Lrule">
<content stylecode="bold underline">Serotonergic Drugs</content>
</td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Rrule Lrule">Clinical Impact</td>
<td stylecode="Rrule">The concomitant use of ADDERALL XR and serotonergic drugs increases the risk of serotonin syndrome.</td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Rrule Lrule">Intervention</td>
<td stylecode="Rrule">Initiate with lower doses and monitor patients for signs and symptoms of serotonin syndrome, particularly during ADDERALL XR initiation or dosage increase. If serotonin syndrome occurs, discontinue ADDERALL XR and the concomitant serotonergic drug(s) <content stylecode="italics">[see <linkhtml href="#S5.6">WARNINGS AND PRECAUTIONS (5.6)</linkhtml>]</content>.</td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Rrule Lrule">Examples</td>
<td stylecode="Rrule">selective serotonin reuptake inhibitors (SSRI), serotonin norepinephrine reuptake inhibitors (SNRI), triptans, tricyclic antidepressants, fentanyl, lithium, tramadol, tryptophan, buspirone, St. John's Wort</td>
</tr>
<tr stylecode="Botrule">
<td colspan="2" stylecode="Rrule Lrule">
<content stylecode="bold underline">CYP2D6 Inhibitors</content>
</td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Rrule Lrule">Clinical Impact</td>
<td stylecode="Rrule">The concomitant use of ADDERALL XR and CYP2D6 inhibitors may increase the exposure of ADDERALL XR compared to the use of the drug alone and increase the risk of serotonin syndrome.</td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Rrule Lrule">Intervention</td>
<td stylecode="Rrule">Initiate with lower doses and monitor patients for signs and symptoms of serotonin syndrome particularly during ADDERALL XR initiation and after a dosage increase. If serotonin syndrome occurs, discontinue ADDERALL XR and the CYP2D6 inhibitor <content stylecode="italics">[see <linkhtml href="#S5.6">WARNINGS AND PRECAUTIONS (5.6)</linkhtml> and <linkhtml href="#LINK_a14fe708-6cd8-4ae9-8bde-837a21107ab3">OVERDOSAGE (10)</linkhtml>]</content>.</td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Rrule Lrule">Examples</td>
<td stylecode="Rrule">paroxetine and fluoxetine (also serotonergic drugs), quinidine, ritonavir</td>
</tr>
<tr stylecode="Botrule">
<td colspan="2" stylecode="Rrule Lrule">
<content stylecode="bold underline">Alkalinizing Agents</content>
</td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Rrule Lrule">Clinical Impact</td>
<td stylecode="Rrule">Increase blood levels and potentiate the action of amphetamine.</td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Rrule Lrule">Intervention</td>
<td stylecode="Rrule">Co-administration of ADDERALL XR and gastrointestinal or urinary alkalinizing agents should be avoided.</td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Rrule Lrule">Examples</td>
<td stylecode="Rrule">Gastrointestinal alkalinizing agents (e.g., sodium bicarbonate). Urinary alkalinizing agents (e.g. acetazolamide, some thiazides).</td>
</tr>
<tr stylecode="Botrule">
<td colspan="2" stylecode="Rrule Lrule">
<content stylecode="bold underline">Acidifying Agents</content>
</td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Rrule Lrule">Clinical Impact</td>
<td stylecode="Rrule">Lower blood levels and efficacy of amphetamines.</td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Rrule Lrule">Intervention</td>
<td stylecode="Rrule">Increase dose based on clinical response.</td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Rrule Lrule">Examples</td>
<td stylecode="Rrule">Gastrointestinal acidifying agents (e.g., guanethidine, reserpine, glutamic acid HCl, ascorbic acid).<br/>Urinary acidifying agents (e.g., ammonium chloride, sodium acid phosphate, methenamine salts).</td>
</tr>
<tr stylecode="Botrule">
<td colspan="2" stylecode="Rrule Lrule">
<content stylecode="bold underline">Tricyclic Antidepressants</content>
</td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Rrule Lrule">Clinical Impact</td>
<td stylecode="Rrule">May enhance the activity of tricyclic or sympathomimetic agents causing striking and sustained increases in the concentration of d-amphetamine in the brain; cardiovascular effects can be potentiated.</td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Rrule Lrule">Intervention</td>
<td stylecode="Rrule">Monitor frequently and adjust or use alternative therapy based on clinical response.</td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Rrule Lrule">Examples</td>
<td stylecode="Rrule">desipramine, protriptyline</td>
</tr>
<tr stylecode="Botrule">
<td colspan="2" stylecode="Rrule Lrule">
<content stylecode="bold underline">Proton Pump Inhibitors</content>
</td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Rrule Lrule">Clinical Impact</td>
<td stylecode="Rrule">Time to maximum concentration (Tmax) of amphetamine is decreased compared to when administered alone.</td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Rrule Lrule">Intervention</td>
<td stylecode="Rrule">Monitor patients for changes in clinical effect and adjust therapy based on clinical response.</td>
</tr>
<tr>
<td stylecode="Rrule Lrule">Examples</td>
<td stylecode="Rrule">omeprazole</td>
</tr>
</tbody>
</table>